![Octapharma USA Announces FDA Approval for 2nd Octagam® 10% Manufacturing Site, Expanding Product Availability | Business Wire Octapharma USA Announces FDA Approval for 2nd Octagam® 10% Manufacturing Site, Expanding Product Availability | Business Wire](https://mms.businesswire.com/media/20150126005103/en/450261/5/octagam_USA_drops_20g.jpg)
Octapharma USA Announces FDA Approval for 2nd Octagam® 10% Manufacturing Site, Expanding Product Availability | Business Wire
![Intravenous Immune Globulin (IVIg) – A newly approved therapeutic option for the treatment of adult dermatomyositis - Myositis Support and Understanding Intravenous Immune Globulin (IVIg) – A newly approved therapeutic option for the treatment of adult dermatomyositis - Myositis Support and Understanding](https://understandingmyositis.org/wp-content/uploads/2022/04/Octagam-DM-Speaker-Presentation_Aggarwal_April-5-2022.png)
Intravenous Immune Globulin (IVIg) – A newly approved therapeutic option for the treatment of adult dermatomyositis - Myositis Support and Understanding
![Octapharma Plasma to spend $950,000.00 to occupy 8,318 square feet of space in Houston Texas. - intelligence360 Octapharma Plasma to spend $950,000.00 to occupy 8,318 square feet of space in Houston Texas. - intelligence360](https://i0.wp.com/www.intelligence360.news/wp-content/uploads/2021/01/OCTAPHARMA.jpg?fit=1200%2C620&ssl=1)